doi: 10.1111/dme.14780 33 TranSRetnakaranRZinmanBKramerCK
Richard Siegel, an endocrinologist and codirector of the Diabetes and Lipid Center at Tufts Medical Center
The largest phase 2 study published on retatrutide, which included 338 non-diabetics, indicated comparable side effects
Semaglutide was administered weekly at the relatively lower doses of 0.25mg/week for the first 4 weeks, and then at 0.5mg/week during weeks 5-8
Nausea is the most common side effect, particularly during dose escalation phases Vomiting, diarrhoea, and decreased appetite were also frequently reported Side effects typically peaked early and diminished over weeks at each dose level Dose holds rather than discontinuation are recommended for tolerability issues Dietary adjustments significantly reduce the impact of GI side effects How Retatrutide Compares to Other Weekly Injectables Placing retatrutide in context alongside currently available weekly injectables helps to illustrate why there is such widespread anticipation around its eventual approval
It's sometimes prescribed off-label for that purpose
